GLP-1 Drugs Protect Hearts; Aspirin Fails Cancer Test

Two Findings That Change How Millions Are Treated

Two major research developments published in early 2026 are forcing physicians around the world to rethink established treatment protocols. GLP-1 receptor agonists — the class of drugs behind blockbuster names like Ozempic, Wegovy, and Mounjaro — have demonstrated meaningful cardiac protection in patients who have survived a heart attack. Meanwhile, a comprehensive Cochrane review has dealt a serious blow to the decades-long practice of recommending daily aspirin to prevent colorectal cancer in ordinary, average-risk patients.

GLP-1 Drugs: Far More Than Weight Loss

Originally approved to treat obesity and type 2 diabetes, GLP-1 receptor agonists are rapidly accumulating evidence as powerful cardiovascular medicines. A landmark meta-analysis published in the Journal of the American College of Cardiology (JACC) in late 2025 analyzed 21 randomized controlled trials covering 99,599 patients across more than 321,000 patient-years. The verdict was unambiguous: GLP-1 drugs delivered "conclusive high-certainty evidence" of reductions in all-cause mortality, cardiovascular death, and major adverse cardiovascular events (MACE).

The post-heart attack picture is especially striking. Research presented at the ASPC 2025 Congress on CVD Prevention found that among patients who suffered a ST-elevation myocardial infarction (STEMI) — the most severe type of heart attack — those already on GLP-1 therapy experienced MACE in 57.2% of cases, compared to 66.7% among non-users. Recurrent heart attacks also fell sharply: 41.2% versus 53.2%. Hospital readmission rates within 30 days dropped from 12.7% to 9.3%.

The landmark SELECT trial, published in the New England Journal of Medicine, had already shown that semaglutide reduced the composite risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% over 33 months among overweight or obese patients without diabetes — and crucially, these benefits appeared independent of how much weight patients actually lost, suggesting the drugs act directly on the cardiovascular system through anti-inflammatory and endothelial-protective mechanisms.

Medical societies are now calling for updated guidelines that formally recognize GLP-1 agonists as cardioprotective agents, not merely metabolic drugs.

Aspirin and Colon Cancer: A Crumbling Consensus

On the cancer prevention front, the news is sobering for proponents of low-dose aspirin. A comprehensive Cochrane systematic review published in February 2026 analyzed 10 randomized controlled trials with 124,837 participants and reached a clear conclusion: aspirin probably does not reduce the risk of colorectal cancer within the first 5 to 15 years of use in people at average risk.

While some studies hinted at a possible protective benefit after more than 10 to 15 years of continuous use, researchers at West China Hospital of Sichuan University — who led the review — rated that evidence as having "very low" certainty. Against any potential long-term gain, aspirin carries immediate and serious risks: the review confirmed it increases the likelihood of severe extracranial bleeding and probably raises the risk of hemorrhagic stroke.

"The current evidence does not support a blanket recommendation for aspirin use purely to prevent bowel cancer," the Cochrane authors concluded, calling for precision-based prevention strategies using individual molecular risk profiles.

The findings challenge guidelines in multiple countries that have, in various forms, endorsed aspirin for cancer chemoprevention — a practice that has influenced millions of prescriptions globally.

A Turning Point for Preventive Medicine

Taken together, these two findings illustrate the rapidly shifting landscape of preventive medicine. Drugs once dismissed as niche diabetes or weight-loss therapies are proving to be broad-spectrum cardiovascular protectors, while a household medication long assumed to double as a cancer shield has now been shown to offer little benefit — and meaningful harm — in the general population.

Clinicians face the task of translating this evidence into individual patient decisions, weighing risks, comorbidities, and emerging molecular data. For GLP-1 drugs, expanded cardiac indications appear increasingly inevitable. For aspirin, the era of routine colon cancer prevention may be drawing to a close.